Malin Corporation Plc

Regulatory Filings • Jan 18, 2021

National Storage Mechanism | Additional information

RNS Number : 9355L

Malin Corporation PLC

18 January 2021

Malin Corporation plc

Immunocore Files for Potential Initial Public Offering on the Nasdaq Global Market

Dublin-Ireland, 18 January 2021: Malin Corporation plc. (Euronext Growth Dublin:MLC) (Malin), a company investing in highly innovative life sciences companies,  today notes that its investee company, Immunocore,  has filed a registration statement on Form F-1 (Registration Statement) with the US Securities and Exchange Commission (SEC) relating to a proposed initial public offering in the United States of American Depositary Shares (ADSs) of Immunocore, each representing one ordinary share of Immunocore. All ADSs to be sold in the proposed initial public offering will be offered by Immunocore. The number of ADSs to be sold and the pricing terms for the proposed IPO have not yet been determined.

Immunocore has applied to list its ADSs on the Nasdaq Global Market under the symbol "IMCR". The number of ADSs to be offered and the price terms for the proposed offering have not yet been determined. The initial public offering is subject to market conditions, and there can be no assurance as to whether, or when, the offering may be completed or as to the actual size or terms of the offering.

The Registration Statement relating to the ADSs has been filed with the SEC but has not yet become effective. The ADSs may not be sold, nor may offers to buy be accepted, prior to the time the Registration Statement becomes effective. The offering will be made only by means of a prospectus. A copy of the preliminary prospectus, when available, may be obtained from the SEC's EDGAR database and contains further information relating to Immunocore.

This press release does not constitute an offer to sell or the solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

ENDS

About Malin Corporation plc

Malin (Euronext Growth Dublin:MLC) is a company investing in highly innovative life sciences companies. Its purpose is to create shareholder value through the application of long-term capital and operational and strategic expertise to a diverse range of global healthcare businesses. Malin has a focus on innovative businesses underpinned by exceptional science and works with its investee companies, providing strategic and financial support to enable them to reach their value potential. Malin is headquartered and domiciled in Ireland and listed on the Euronext Growth Dublin. For more information visit www.malinplc.com 

About Immunocore

Immunocore is a late-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX - Immune mobilising monoclonal TCRs Against X disease - designed to treat a broad range of diseases, including cancer, infectious and autoimmune.

For further information please contact:

Malin

Jessica Bergin, Investor Relations & External Reporting

Tel: +353 (0)1 901 5700

investorrelations@malinplc.com

Davy Corporate Finance (Euronext Growth Adviser & Joint Broker)

Brian Garrahy / Daragh O'Reilly

Tel: +353 1 679 6363

Liberum (Joint Broker)

Bidhi Bhoma / Euan Brown

Tel: +44 (0) 20 3100 2000

Powerscourt (Irish Media enquiries)         

Jack Hickey

Tel: +353 83 4488339                            

malin@powerscourt-group.com  

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCGPUAWGUPGGCM